Week in Review: The Latest from PhRMA

Priscilla VanderVeer
Priscilla VanderVeer December 11, 2015

Week in Review: The Latest from PhRMA.

Share This

week-in-reviewPart D’s Six Protected Classes: The latest Conversations forum asks leading health experts why Medicare Part D’s protected classes are important for patients. See what they had to say. 

Critics Wrong on Spending Claims: Once again, comments about new medicines wreaking financial havoc have been proven wrong by the competitive marketplace. Read what these doomsday talks fail to keep in context. 

Medicines in Development: PhRMA and the Association of Black Cardiologists released the 2015 Medicines in Development report, which looks at the nearly 200 medicines in the pipeline for heart disease and stroke. Check out the report for treatments in development for the 85 million Americans living with some type of cardiovascular disease.

Tropical Disease Research: The latest G-FINDER report from Policy Cures on tropical disease research details the 28 percent increase in the biopharmaceutical industry’s 2014 funding for research into new treatments and cures for neglected tropical diseases such as Ebola, malaria and other infectious diseases. Read more about the report.  

From Hope to Cures: Patients like former President Jimmy Carter and Maryland Governor Larry Hogan, announced they were cancer-free recently within the last week and both have lauded the role innovative new cures developed by the biopharmaceutical industry have played in their fight against the disease. Learn more about the 836 medicines in development to help patients fight cancer.

Medicare Monday: With the open enrollment period ending this week, the latest Medicare Monday post encouraged seniors to take advantage of the shopping period to review their plan options.